SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Dublin, Nov. 08, 2017 -- The "RNAi - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.
Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.
The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2016 to 2026. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.
Profiles of 162 companies involved in developing RNAi technologies are presented along with 233 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs.
Key Topics Covered:
Executive Summary
1. Technologies for suppressing gene function
2. RNAi Technologies
3. MicroRNA
4. Methods of delivery in RNAi
5. RNAi in Research
6. RNAi in drug discovery
7. Therapeutic applications of RNAi
8. Safety, regulatory and patent issues
9. Markets for RNAi Technologies
10. Companies involved in RNAi Technologies
11. References
For more information about this report visit https://www.researchandmarkets.com/research/7xlhz7/rnai
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics
